Apollomics Inc. income statement

In fiscal 2025, Apollomics Inc. reported revenue of $8.5m and net income of −$10.9m, or −$7.57 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Apollomics Inc.: income statement, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	0	0	0	0	0	9
Research and development	31	36	35	34	25	6
General and administrative	11	15	10	21	18	12
Operating income	—	—	1	—	—	—
Interest expense	0	0	0	0	0	0
Income before tax	−75	−95	−241	−173	−54	−11
Income tax	−0	0	0	0	0	0
Net income	−75	−95	−241	−173	−54	−11
Diluted EPS	−$21.00	−$337.00	−$844.95	−$231.99	−$52.80	−$7.57
Diluted shares (average)	4m	—	—	—	1m	1m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ACRS vs APLM APLM vs COYA ADAG vs APLM

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Apollomics Inc.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Apollomics Inc.